perties offers scope for new and improved versions of therapeutic proteins with improved function and stability. The protein engineering market products is growing due to an increase in prevalence of cancer, autoimmune, inflammatory and infectious diseases. These diseases need a targeted therapeutic approach for treatment, which is achieved by therapeutic proteins. Monoclonal antibody is the fastest growing product segment in the market with more than 50% market share. There are more than 25 monoclonal antibodies approved for therapeutics; 10 of these are blockbuster drugs with more than $1 billion in annual revenue. Other products like insulin analogs, EPO, enzymes, and growth hormones are expected to grow at a medium pace.
U.S. and Europe have been major protein engineering market products; however, Asia is set to grow at a faster pace with India's growth in the field of biotechnology and Chinas interest in the research of monoclonal antibodies. Indonesia is the fourth-largest diabetic population nation, and South Koreas growing cancer incidence rate is expected to propel the market for protein therapeutics in the region.
Key players in the market include Genetech (U.S.), Amgen(U.S.), Roche (Switzerland), Eli Lilly (U.S.), Novartis (Switzerland), GSK (U.K.), BMS (U.S.), Johnson & Johnson(U.S.), Merck (U.S.), Pfizer (U.S.), Sanofi (France), Affymax (U.S.), Biogen Idec (U.S.), and Medimmune (U.S.).
Buy a copy of this report @
MarketsandMarkets is a global marPage: 1 2 3 Related biology technology :1
. Tenfold boost in ability to pinpoint proteins in cancer cells2
. New Applications of Pressure BioSciences PCT Platform Prominently Featured at Scientific Conference on Technologies for Protein Research3
. Penn researchers develop protein passport that help nanoparticles get past immune system4
. Dr. Wayne Hachey Joins Protein Sciences Leadership Team5
. transOMIC technologies Releases Tagged ORF Clones for Protein Expression6
. Waters Unveils Industrys First Integrated LC/MS Platform for Proteins, Peptides, and Glycans Analysis at WCBP 20137
. CSL Behring enrolls first patient in global pediatric Phase III pivotal study of recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) to treat hemophilia B8
. Intrinsically disordered proteins: A conversation with Rohit Pappu9
. NIH media availability: Protein linked to increased risk of heart failure and death in older adults10
. Protein that helps tumor blood vessels mature could make cancer drugs more effective11
. Frost & Sullivan Recognizes MicroProtein Technologies for its Path-Breaking Production Technology for Recombinant Proteins in Bacteria